Ellis E F, Morris H G, Kiechel F, Pollock J D, Strand L J
J Clin Pharmacol. 1979 Oct;19(10):675-83. doi: 10.1002/j.1552-4604.1979.tb01631.x.
Efficacy and safety of alternate-day prednisolone compared to single daily cloprednol were evaluated over a six-week period in 11 children with severe asthma requiring in-residence medical supervision and long-term corticosteroid therapy. Clinical indices of efficacy, including daily pulmonary symptom scores, number of asthma attacks, asthma severity scores, and bronchodilator usage, all favored cloprednol. Afternoon pulmonary function tests (FEV1, FVC, and PEFR) were all significantly improved during the cloprednol period. Although plasma cortisol values remained within the broad range of normal during the cloprednol period, mean values were consistent with partial pituitary-adrenal suppression similar in degree to that observed 24 hours after administration of an alternate-day program of prednisolone therapy. The results of this trial showed cloprednol in single daily doses to be more effective than prednisolone in alternate doses for the treatment of children with severe asthma.
在六周的时间里,对11名需要住院医疗监护和长期皮质类固醇治疗的重度哮喘儿童,评估了隔日服用泼尼松龙与每日单次服用氯泼尼醇的疗效和安全性。疗效的临床指标,包括每日肺部症状评分、哮喘发作次数、哮喘严重程度评分和支气管扩张剂使用情况,均显示氯泼尼醇更具优势。在氯泼尼醇治疗期间,下午的肺功能测试(第一秒用力呼气容积、用力肺活量和呼气峰值流速)均有显著改善。虽然在氯泼尼醇治疗期间血浆皮质醇值仍在正常的较宽范围内,但平均值与部分垂体 - 肾上腺抑制一致,其程度与隔日服用泼尼松龙治疗方案给药24小时后观察到的相似。该试验结果表明,每日单次剂量的氯泼尼醇在治疗重度哮喘儿童方面比隔日剂量的泼尼松龙更有效。